You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Prodrug Treatment for CML

    SBC: Inhibikase Therapeutics, Inc.            Topic: 399

    Inhibikase Therapeutics is a clinical stagebio pharmaceutical company that has developed a novel prodrug formulation for the popular anticancer agent GleevecGleevectreatment is commonly accompanied by significantburdensome gastrointestinal side effectsfatigue and myalgias that erode therapy success due to poor patient complianceInhibikaseandapos s prodrug of GleevecIkTProProcompletely blunts these ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NIAAA

    Abstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a protein drug for pancreatic cancer treatment

    SBC: ProDa BioTech L.L.C.            Topic: NCI

    Abstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Large Pore SPP Particles for Protein Separations

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Data Intelligence & Advanced Analytics to Reduce Drug Diversion across the Care Delivery Cycle and Drug Supply Chain in Health Systems

    SBC: Invistics Corporation            Topic: NIDA

    This SBIR project will research mechanisms to detect when Health Care WorkersHCWsin hospitals steal ordivertlegal drugs either to abuse themselves or to illegally sell to othersWe focus on HCWs in hospitals because of the alarming rates of substance abuse and diversion in hospitalswith multiple studies finding roughlyof our nation s nursesanesthesiologistsand pharmacists are currently diverting dr ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Microhook nerve tape: A nerve repair coaptation aid

    SBC: Axion Biosystems, Inc.            Topic: 101

    Project Summary We will finalize development of a microhook based device for quick and consistently effective repair of nerve injuriesThismicrohook nerve tapeconsists of an array of microscale hooksdistributed across a fineflexible meshwork and embedded in a biologic backingThis device will be used during nerve repair surgeries in place of microsutures to wrap around and bind the approximated ends ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government